ASH 2023 | Alnuctamab, a BCMA x CD3 TCE, in the treatment of multiple myeloma
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, shares results from a first-in-human trial (NCT03486067) evaluating alnuctamab, a BCMA x CD3 bispecific T-cell engager (TCE), in the treatment of relapsed/refractory (R/R) multiple myeloma (MM). This trial utilized a step-up regimen followed by monthly subcutaneous administration of a fixed target dose of 30mg, which achieved an overall response rate (ORR) of 68% and had low rates of infection. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Adaptive biotechnologies: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding; Genentech: Research Funding; AbbVie: Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Research Funding.
